Meanwhile shares in Novavax advanced 1.8% after the drugmaker finally announced the initiation of the pivotal Phase 3 study in the US and Mexico of its COVID-19 vaccine candidate, NVX-CoV2373. The start of the trial has been delayed twice already. Novavax is currently conducting multiple trials across different phases in the US, UK, South Africa and Australia, with results from these trials expected to be released in the first quarter of 2021.